OBJECTIVES: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10-4 Methods: Study population was from ALL study groups in Europe managed in national study protocols 2000-2014. MRD was measured by polymerase chain reaction or flow cytometry. Patients were age ≥15 years at initial ALL diagnosis. Patients were excluded if exposed to blinatumomab within 18 months of baseline or prior alloHSCT. RESULTS: Of 272 patients in CR1, baseline MRD was ≥10-1, 10-2 to <10-1, 10-3 to <10-2, and 10-4 to <10-3 in 15 (6%), 71 (26%), 109 (40%), and 77 (28%) patients, respectively. Median duration of complete remission (DoR) was 18.5 months (95% confidence interval [CI], 11.9-27.2), median relapse-free survival (RFS) was 12.4 months (95% CI, 10.0-19.0) and median overall survival (OS) was 32.5 months (95% CI, 23.6-48.0). Lower baseline MRD level (P ≤ .0003) and white blood cell count <30,000/µL at diagnosis (P ≤ .0053) were strong predictors for better RFS and DoR. Allogeneic hematopoietic stem cell transplantation (alloHSCT) was associated with longer RFS (hazard ratio [HR], 0.59; 95% CI, 0.41-0.84) and DoR (HR, 0.43; 95% CI, 0.29-0.64); the association with OS was not significant (HR, 0.72; 95% CI, 0.50-1.05). DISCUSSION: In conclusion, RFS, DoR, and OS are relatively short in patients with MRD-positive ALL, particularly at higher MRD levels. AlloHSCT may improve survival but has limitations. Alternative approaches are needed to improve outcomes in MRD-positive ALL.
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia / N. Gökbuget, H. Dombret, S. Giebel, M. Bruggemann, M. Doubek, R. Foà, D. Hoelzer, C. Kim, G. Martinelli, E. Parovichnikova, A. Rambaldi, J. Ribera, M. Schoonen, J.M. Stieglmaier, G. Zugmaier, R. Bassan. - In: HEMATOLOGY. - ISSN 1607-8454. - 24:1(2019 Jan 01), pp. 337-348.
|Titolo:||Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia|
|Parole Chiave:||Acute lymphoblastic leukemia; allogeneic stem cell transplant; minimal residual disease; MRD; Adolescent; Adult; Aged; Allografts; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Philadelphia Chromosome; Survival Rate; Hematopoietic Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Hematology|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||1-gen-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/16078454.2019.1567654|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Minimal residual disease level predicts outcome in adults with Ph negative B precursor acute lymphoblastic leukemia.pdf||Publisher's version/PDF||Open Access Visualizza/Apri|